Literature DB >> 25413140

Indirect comparisons in cost-effectiveness analysis: are we being naïve?

J Martin-Broto1.   

Abstract

Mesh:

Year:  2014        PMID: 25413140     DOI: 10.1007/s12094-014-1256-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  4 in total

1.  Indirect comparisons of competing interventions.

Authors:  A M Glenny; D G Altman; F Song; C Sakarovitch; J J Deeks; R D'Amico; M Bradburn; A J Eastwood
Journal:  Health Technol Assess       Date:  2005-07       Impact factor: 4.014

2.  Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain.

Authors:  G Villa; L J Hernández-Pastor; M Guix; J Lavernia; M Cuesta
Journal:  Clin Transl Oncol       Date:  2014-07-01       Impact factor: 3.405

Review 3.  Indirect comparisons: a review of reporting and methodological quality.

Authors:  Sarah Donegan; Paula Williamson; Carrol Gamble; Catrin Tudur-Smith
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

Review 4.  Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews.

Authors:  Fujian Song; Yoon K Loke; Tanya Walsh; Anne-Marie Glenny; Alison J Eastwood; Douglas G Altman
Journal:  BMJ       Date:  2009-04-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.